Hjem › T-celle-lymfom › Illinois
T-celle-lymfom kliniske forsøg i Illinois
7 studier for T-celle-lymfom søger deltagere på steder i Illinois.
Byer i Illinois
Officiel studietekst (engelsk)
Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma
- Northwestern University, Chicago
- University of Illinois, Chicago
- Northwestern Medicine Cancer Center Kishwaukee, DeKalb
- og 6 flere
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 2. okt. 2026 · NCT04803201Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma
- North Western University Robert H. Lurie Comprehensive Cancer Center RHLCCC, Chicago
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 25. sep. 2026 · NCT06561048Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy
- Loyola Center for Health at Burr Ridge, Burr Ridge
- Loyola Medicine Homer Glen, Homer Glen
- Loyola University Medical Center, Maywood
- og 1 flere
RekruttererFase 3
Alder 18 til 75 · Alle køn · Opdateret 14. sep. 2026 · NCT06724237A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
- University of Chicago Medical Center, Chicago
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 19. aug. 2026 · NCT04104776A Registry for People With T-cell Lymphoma
- Northwestern Medicine (Data Collection), Chicago
RekruttererObservationsstudie
Alle aldre · Alle køn · Opdateret 20. maj 2026 · NCT05978141Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma
- Northwestern University, Robert H. Lurie Comprehensive Cancer Center, Chicago
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 22. sep. 2025 · NCT04234048Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
- Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago
RekruttererFase 1
Alder 1 til 21 · Alle køn · Opdateret 6. dec. 2024 · NCT05476770Fra ClinicalTrials.gov, data hentet 3. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.